Rapidly Evolving Insulin Landscape: Ultrashort Acting and Ultralong Acting

Since the discovery of insulin in 1921, there has been remarkable evolution in insulin treatment for diabetes, with modern insulin analogues utilizing highly engineered recombinant technology. The purpose of this review is to focus on two revolutionary developments in contemporary insulin therapy: once-weekly ultralong-acting basal insulins and ultrashort-acting bolus insulins. Insulin icodec and insulin efsitora alfa represent a unique shift in basal insulin delivery, offering the convenience of once-weekly administration, flat pharmacokinetic profiles, and glycemic efficacy and safety comparable to those of daily basal analogues while reducing injection burden and improving patient satisfaction. With regard to bolus therapy, faster-acting aspart and ultrarapid lispro achieve accelerated absorption through novel excipient engineering, enabling more flexible mealtime dosing and improved postprandial glucose control compared to their traditional counterparts. Looking ahead, there are promising innovations on the horizon, including glucose-responsive insulins, artificial intelligence-driven automated insulin delivery, and the continued pursuit of oral insulin. Together, these advances represent an accelerating trajectory toward more physiological, convenient, and, most importantly, safe insulin therapy.

Authors

Institutions

Publication Details

Journal
Annual Review of Medicine
Published
2026-11-12
DOI
https://doi.org/10.1146/annurev-med-042425-010403
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rapidly Evolving Insulin Landscape: Ultrashort Acting and Ultralong Acting

Rishi B. Gupta, HARPREET SINGH BAJAJ, Suhani K. Arora, Navneet Sohi
Annual Review of Medicine
Diabetes Management and Research
article

Rapidly Evolving Insulin Landscape: Ultrashort Acting and Ultralong Acting

Rishi B. Gupta, HARPREET SINGH BAJAJ, Suhani K. Arora, Navneet Sohi
article en

Abstract

Since the discovery of insulin in 1921, there has been remarkable evolution in insulin treatment for diabetes, with modern insulin analogues utilizing highly engineered recombinant technology. The purpose of this review is to focus on two revolutionary developments in contemporary insulin therapy: once-weekly ultralong-acting basal insulins and ultrashort-acting bolus insulins. Insulin icodec and insulin efsitora alfa represent a unique shift in basal insulin delivery, offering the convenience of once-weekly administration, flat pharmacokinetic profiles, and glycemic efficacy and safety comparable to those of daily basal analogues while reducing injection burden and improving patient satisfaction. With regard to bolus therapy, faster-acting aspart and ultrarapid lispro achieve accelerated absorption through novel excipient engineering, enabling more flexible mealtime dosing and improved postprandial glucose control compared to their traditional counterparts. Looking ahead, there are promising innovations on the horizon, including glucose-responsive insulins, artificial intelligence-driven automated insulin delivery, and the continued pursuit of oral insulin. Together, these advances represent an accelerating trajectory toward more physiological, convenient, and, most importantly, safe insulin therapy.

Annual Review of Medicine
University of Alberta (CA), Trillium Health Centre (CA), LMC Diabetes & Endocrinology (Canada) (CA)
Good health and well-being
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon